Last reviewed · How we verify

NCT04322305: GABI2

Pregabalin Trial for the Treatment of Alcohol Use Disorder

Suspended Phase 2 Last updated 14 February 2025
What this trial tests

Phase 2 trial testing Pregabalin in Alcohol Use Disorder in 50 participants. Suspended.

Timeline
11 January 2021
Primary endpoint
30 June 2025
30 June 2025

Quick facts

Lead sponsorNew York State Psychiatric Institute
PhasePhase 2
StatusSuspended
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment50
Start date11 January 2021
Primary completion30 June 2025
Estimated completion30 June 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

New York State Psychiatric Institute

Who can join

Adults 18 to 65, any sex, with Alcohol Use Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In a 10-week randomized double-blind placebo-controlled outpatient pilot trial the efficacy of pregabalin in the treatment of alcohol dependence will be studied in 50 treatment-seeking outpatients. Participants will report drinking a minimum of 5 standard drinks for men or 4 standard drinks for women at least 4 days per week over the past 28 days.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Pregabalin

Trials testing the same drug.

Other recruiting trials for Alcohol Use Disorder

Currently open trials in the same condition.

Other New York State Psychiatric Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04322305.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing